Antimycobacterial Activity of a New Peptide Polydim-I Isolated from Neotropical Social Wasp Polybia dimorpha

Mycobacterium abscessus subsp. massiliense, a rapidly growing mycobacteria (RGM) that is becoming increasingly important among human infectious diseases, is virulent and pathogenic and presents intrinsic resistance to several antimicrobial drugs that might hamper their elimination. Therefore, the identification of new drugs to improve the current treatment or lower the risk of inducing resistance is urgently needed. Wasp venom primarily comprises peptides that are responsible for most of the biological activities in this poison. Here, a novel peptide Polydim-I, from Polybia dimorpha Neotropical wasp, was explored as an antimycobacterial agent. Polydim-I provoked cell wall disruption and exhibited non-cytotoxicity towards mammalian cells. Polydim-I treatment of macrophages infected with different M. abscessus subsp. massiliense strains reduced 40 to 50% of the bacterial load. Additionally, the Polydim-I treatment of highly susceptible mice intravenously infected with M. abscessus subsp. massiliense induced 0.8 to 1 log reduction of the bacterial load in the lungs, spleen, and liver. In conclusion, this is the first study to show the therapeutic potential of a peptide derived from wasp venom in treating mycobacteria infections. Polydim-I acts on the M. abscessus subsp. massiliense cell wall and reduce 40–90% of the bacterial load both in vitro and in vivo. The presented results encourage further studies on the use of Polydim-I as one of the components for M. abscessus subsp. massiliense treatment.

[1]  Lisa K. Woolhiser,et al.  Importance of Confirming Data on the In Vivo Efficacy of Novel Antibacterial Drug Regimens against Various Strains of Mycobacterium tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[2]  R. Hancock,et al.  Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models , 2013, PloS one.

[3]  G. Pirri,et al.  Antimicrobial peptides: an overview of a promising class of therapeutics , 2007, Central European Journal of Biology.

[4]  K. Lohner.  New strategies for novel antibiotics: peptides targeting bacterial cell membranes. , 2009, General physiology and biophysics.

[5]  Kairong Wang,et al.  Antitumor effects, cell selectivity and structure–activity relationship of a novel antimicrobial peptide polybia-MPI , 2008, Peptides.

[6]  Michael R. Yeaman,et al.  Mechanisms of Antimicrobial Peptide Action and Resistance , 2003, Pharmacological Reviews.

[7]  Minming Zhang,et al.  Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis , 2013, The Journal of international medical research.

[8]  M. Palma,et al.  Peptide diversity in the venom of the social wasp Polybia paulista (Hymenoptera): A comparison of the intra- and inter-colony compositions , 2014, Peptides.

[9]  R. Hancock,et al.  Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. , 2013, International journal of antimicrobial agents.

[10]  M. Collins,et al.  Effects of colonial morphology and tween 80 on antimicrobial susceptibility of Mycobacterium paratuberculosis , 1990, Antimicrobial Agents and Chemotherapy.

[11]  A. Kipnis,et al.  Emergence of nosocomial Mycobacterium massiliense infection in Goiás, Brazil. , 2008, Microbes and infection.

[12]  I. Orme,et al.  Rapid In Vivo Screening of Experimental Drugs for Tuberculosis Using Gamma Interferon Gene-Disrupted Mice , 2003, Antimicrobial Agents and Chemotherapy.

[13]  M. Hornef,et al.  Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines. , 2012, Current drug targets.

[14]  M. Jackson,et al.  Increased Virulence of an Epidemic Strain of Mycobacterium massiliense in Mice , 2011, PloS one.

[15]  J. Tzen,et al.  Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan , 2011, Peptides.

[16]  H. Svanström,et al.  Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study , 2014, BMJ : British Medical Journal.

[17]  K. Heinig,et al.  Bioanalysis of therapeutic peptides: differentiating between total and anti-drug antibody bound drug using liquid chromatography-tandem mass spectrometry quantitation. , 2013, Journal of chromatography. A.

[18]  E. Tortoli,et al.  Characterization of Mycobacteria from a Major Brazilian Outbreak Suggests that Revision of the Taxonomic Status of Members of the Mycobacterium chelonae-M. abscessus Group Is Needed , 2009, Journal of Clinical Microbiology.

[19]  M. Lourenço,et al.  Epidemic of Postsurgical Infections Caused by Mycobacterium massiliense , 2009, Journal of Clinical Microbiology.

[20]  Fengjing Jia,et al.  Dual antifungal properties of cationic antimicrobial peptides polybia-MPI: Membrane integrity disruption and inhibition of biofilm formation , 2014, Peptides.

[21]  S. Shin,et al.  Successful Treatment of Mycobacterium massiliense Lung Disease with Oral Antibiotics Only , 2012, Antimicrobial Agents and Chemotherapy.

[22]  Junguang Jiang,et al.  Antimicrobial potency and selectivity of simplified symmetric-end peptides. , 2014, Biomaterials.

[23]  J. Fox.  Antimicrobial peptides stage a comeback , 2013, Nature Biotechnology.

[24]  Amit X. Garg,et al.  Statin Toxicity From Macrolide Antibiotic Coprescription , 2013, Annals of Internal Medicine.

[25]  G. Lalmanach,et al.  Antimicrobial proteins and peptides in human lung diseases: A friend and foe partnership with host proteases. , 2016, Biochimie.

[26]  O. Franco,et al.  In vivo antimicrobial evaluation of an alanine-rich peptide derived from Pleuronectes americanus , 2013, Peptides.

[27]  J. Casanova,et al.  Importance of T Cells, Gamma Interferon, and Tumor Necrosis Factor in Immune Control of the Rapid Grower Mycobacterium abscessus in C57BL/6 Mice , 2007, Infection and Immunity.

[28]  S. Cheney.  Statin Toxicity From Macrolide Antibiotic Coprescription: A Population Based Cohort Study , 2014 .

[29]  A. Kipnis,et al.  Acute Immune Response to Mycobacterium massiliense in C57BL/6 and BALB/c Mice , 2010, Infection and Immunity.

[30]  L. Ramakrishnan,et al.  Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism , 2011, Cell.

[31]  E. Carneiro,et al.  Agelaia MP-I: a peptide isolated from the venom of the social wasp, Agelaia pallipes pallipes, enhances insulin secretion in mice pancreatic islets. , 2012, Toxicon : official journal of the International Society on Toxinology.

[32]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[33]  Y. Hattori,et al.  Activation of macrophages by lactoferrin: secretion of TNF‐α, IL‐8 and NO , 1997 .

[34]  R. Hunter,et al.  Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis. , 2007, Vaccine.

[35]  C. Shyu,et al.  In vitro activity of mastoparan-AF alone and in combination with clinically used antibiotics against multiple-antibiotic-resistant Escherichia coli isolates from animals , 2012, Peptides.

[36]  T. Shim,et al.  A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. , 2014, Respiratory medicine.

[37]  Robert E W Hancock,et al.  Peptide design for antimicrobial and immunomodulatory applications. , 2013, Biopolymers.

[38]  Enrico Tortoli,et al.  Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. , 2011, International journal of systematic and evolutionary microbiology.

[39]  M. A. Marin-Morales,et al.  Cytotoxic, genotoxic/antigenotoxic and mutagenic/antimutagenic effects of the venom of the wasp Polybia paulista. , 2013, Toxicon : official journal of the International Society on Toxinology.

[40]  Po-Ren Hsueh,et al.  Mycobacterium abscessus Complex Infections in Humans , 2015, Emerging infectious diseases.

[41]  Ana Paula Junqueira-Kipnis,et al.  Research Article in Vitro Antimicrobial Susceptibility of Mycobacterium Massiliense Recovered from Wound Samples of Patients Submitted to Arthroscopic and Laparoscopic Surgeries , 2022 .

[42]  C. Fraser,et al.  High-level Relatedness among Mycobacterium abscessus subsp. massiliense Strains from Widely Separated Outbreaks , 2014, Emerging infectious diseases.

[43]  Y. Hattori,et al.  Activation of macrophages by lactoferrin: secretion of TNF-alpha, IL-8 and NO. , 1997, Biochemistry and molecular biology international.

[44]  Soo Hyun Lee,et al.  Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. , 2012, American journal of respiratory and critical care medicine.

[45]  H. Arcuri,et al.  Structure-function relationships of the peptide Paulistine: a novel toxin from the venom of the social wasp Polybia paulista. , 2014, Biochimica et biophysica acta.

[46]  Yi Yan Yang,et al.  Synthetic modifications of the immunomodulating peptide thymopentin to confer anti-mycobacterial activity , 2014, Biomaterials.

[47]  Se Yeon Kim,et al.  Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis , 2013, Nature Medicine.

[48]  B. Mishra,et al.  Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages , 2011, Cellular microbiology.

[49]  Rafael Ponce,et al.  Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. , 2009, Regulatory toxicology and pharmacology : RTP.

[50]  Avinash Sonawane,et al.  Antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects. , 2014, Tuberculosis.